UroGen Pharma Ltd. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
UroGen Pharma Ltd. (URGN) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $784.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-05
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $784.00K.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $864.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $951.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $1.01M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount as first filed |
|---|---|---|
| 2026-06-30 | $784.00K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $864.00K 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $951.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $1.01M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $141.00K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $20.00K 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $122.00K 10-Q · filed 2025-05-12 | $39.00K 10-K · filed 2025-03-10 |
| 2024-09-30 | $60.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $88.00K 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $122.00K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $158.00K 10-K · filed 2024-03-14 | |
| 2023-09-30 | $200.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $248.00K 10-Q · filed 2024-08-13 | |
| 2023-03-31 | $305.00K 10-Q · filed 2024-05-13 | |
| 2022-12-31 | $360.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $431.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $348.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $50.00K 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $69.00K 10-K · filed 2022-03-21 | |
| 2020-12-31 | $173.00K 10-K · filed 2021-03-18 | |
| 2019-12-31 | $345.00K 10-K · filed 2020-03-02 | |
| 2019-09-30 | $328.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $369.00K 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $421.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |